Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens

Schizophrenia Research

Volumn 161, Issue 2-3, 2015, Pages 452-457

  Xu, Su ^a   Gullapalli, Rao P ^a   Frost, Douglas O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Development; Magnetic resonance spectroscopy; Neuroplasticity; Reward system

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REWARD; ANIMAL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LONG EVANS RAT; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; MALE; NUCLEUS ACCUMBENS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RATS, LONG-EVANS;

EID: 84921463782     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.034     Document Type: Article

References (86)

1. Alexander G.C., Gallagher S.A., Mascola A., Moloney R.M., Stafford R.S. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol. Drug Saf. 2011, 20(2):177-184.
2. Andersen S.L., Navalta C.P. Annual research review: new frontiers in developmental neuropharmacology: can long-term therapeutic effects of drugs be optimized through carefully timed early intervention?. J. Child Psychol. Psychiatry 2011, 52(4):476-503.
3. Ansorge M.S., Morelli E., Gingrich J.A. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J. Neurosci. 2008, 28(1):199-207.
4. Azmitia E.C. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull. 2001, 56(5):413-424.
5. Baldessarini R.J. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, 447-484. McGraw-Hil, New York. 10 ed. J.G. Hardman, L.E. Limbird, A.G. Gilman (Eds.).
6. Benoit-Marand M., O'Donnell P. D2 dopamine modulation of corticoaccumbens synaptic responses changes during adolescence. Eur. J. Neurosci. 2008, 27(6):1364-1372.
7. Bolliger C.S., Boesch C., Kreis R. On the use of Cramer-Rao minimum variance bounds for the design of magnetic resonance spectroscopy experiments. Neuroimage 2013, 83:1031-1040.
8. Brady A.M., O'Donnell P. Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J. Neurosci. 2004, 24(5):1040-1049.
9. Brooks J.M., O'Donnell P., Frost D.O. Olanzapine Treatment of Adolescent Rats Alters D2 Modulation of Cortical Inputs to the Nucleus Accumbens in Adulthood. (Manuscript in Preparation) 2014.
10. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14(2):87-96.
11. Cavassila S., Deval S., Huegen C., van Ormondt D., Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001, 14(4):278-283.
12. Cheng-Shannon J., McGough J.J., Pataki C., McCracken J.T. Second-generation antipsychotic medications in children and adolescents. J. Child Adolesc. Psychopharmacol. 2004, 14(3):372-394.
13. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ. 2nd ed.
14. de Bartolomeis A., Buonaguro E.F., Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl) 2013, 225(1):1-19.
15. Del Arco A., Mora F. Glutamate-dopamine in vivo interaction in the prefrontal cortex modulates the release of dopamine and acetylcholine in the nucleus accumbens of the awake rat. J. Neural Transm. 2005, 112(1):97-109.
16. Del Arco A., Mora F. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol. Biochem. Behav. 2008, 90(2):226-235.
17. Di Pietro N.C., Seamans J.K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007, 40(Suppl. 1):S27-S33.
18. Egerton A., Stone J.M. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr. Pharm. Biotechnol. 2012, 13(8):1500-1512.
19. Eyles D., Feldon J., Meyer U. Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl. Psychiatry 2012, 2:e81.
20. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 2003, 6(9):968-973.
21. Frost D.O., Cadet J.L. Effects of drug-induced neurotoxicity on development of neural circuitry: a hypothesis. Br. Res. Rev. 2000, 34:103-118.
22. Frost D.O., Cercio Page S., Carroll C., Kolb B. Early exposure to haloperidol or olanzapine induces long term alterations of dendritic form. Synapse 2010, 64(3):191-199.
23. Gao W.J., Wang Y., Goldman-Rakic P.S. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J. Neurosci. 2003, 23(5):1622-1630.
24. Giedd J.N., Lalonde F.M., Celano M.J., White S.L., Wallace G.L., Lee N.R., Lenroot R.K. Anatomical brain magnetic resonance imaging of typically developing children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48(5):465-470.
25. Goldman P.S. Functional development of the prefrontal cortex in early life and the problem of neuronal plasticity. Exp. Neurol. 1971, 32:366-387.
26. Goto Y., O'Donnell P. Delayed mesolimbic system alteration in a developmental animal model of schizophrenia. J. Neurosci. 2002, 22(20):9070-9077.
27. Goto Y., O'Donnell P. Altered prefrontal cortex-nucleus accumbens information processing in a developmental animal model of schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:398-401.
28. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn. Reson. Med. 1993, 29(6):804-811.
29. Hensch T.K. Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci. 2005, 6(11):877-888.
30. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
31. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
32. Huang Z.J. Activity-dependent development of inhibitory synapses and innervation pattern: role of GABA signalling and beyond. J. Physiol. 2009, 587(Pt 9):1881-1888.
33. Hubel D.H., Wiesel T.N. The period of susceptibility to the physiological effects of unilateral eye closure in kittens. J. Physiol. 1970, 206(2):419-436.
34. Hubel D.H., Wiesel T.N., LeVay S. Plasticity of ocular dominance columns in monkey striate cortex. Phil. Trans. Roy. Soc. Lond. (B) 1977, 278:377-409.
35. Huppé-Gourges F., O'Donnell P. D1-NMDA receptor interactions in the rat nucleus accumbens change during adolescence. Synapse 2012, 66(7):584-591.
36. Huppé-Gourgues F., O'Donnell P. Periadolescent changes of D(2)-AMPA interactions in the rat nucleus accumbens. Synapse 2012, 66(1):1-8.
37. Innocenti G.M., Frost D.O., Illes J. Maturation of visual callosal connections in visually deprived kittens: a challenging critical period. J. Neurosci. 1985, 5:255-267.
38. Johnson M., Kozielska M., Pilla Reddy V., Vermeulen A., Barton H.A., Grimwood S., de Greef R., Groothuis G.M., Danhof M., Proost J.H. Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach. Pharm. Res 2014, 31:2605-2617.
39. Kapetanovic S., Simpson G.M. Review of antipsychotics in children and adolescents. Expert. Opin. Pharmacother. 2006, 7(14):1871-1885.
40. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 1996, 153(4):466-476.
41. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305(2):625-631.
42. Kehagia A.A., Murray G.K., Robbins T.W. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr. Opin. Neurobiol. 2010, 20(2):199-204.
43. Kolaczkowski M., Mierzejewski P., Bienkowski P., Wesolowska A., Newman-Tancredi A. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedeberg's Arch. Pharmacol. 2014, 387(6):545-557.
44. Kolb B., Mychasiuk R., Muhammad A., Li Y., Frost D.O., Gibb R. Experience and the developing prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17186-17193. (Suppl 2).
45. Lenz K.M., Nugent B.M., McCarthy M.M. Sexual differentiation of the rodent brain: dogma and beyond. Front. Neurosci. 2012, 6:26.
46. Levitt P., Harvey J.A., Friedman E., Simansky K., Murphy E.H. New evidence for neurotransmitter influences on brain development. Trends Neurosci. 1997, 20(6):269-274.
47. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31(5):234-242.
48. Llorente-Berzal A., Mela V., Borcel E., Valero M., Lopez-Gallardo M., Viveros M.P., Marco E.M. Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats 2011, Neuropharmacology.
49. Loskutova L.V. The effects of a serotoninergic substrate of the nucleus accumbens on latent inhibition. Neurosci. Behav. Physiol. 2001, 31(1):15-20.
50. Lu B., Wang K.H., Nose A. Molecular mechanisms underlying neural circuit formation. Curr. Opin. Neurobiol. 2009, 19(2):162-167.
51. Marek G.J. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. Int. Rev. Neurobiol. 2007, 78:165-192.
52. McCracken J.T., Suddath R., Chang S., Thakur S., Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J. Child Adolesc. Psychopharmacol. 2008, 18(5):501-508.
53. McKnight R.F., Park R.J. Atypical antipsychotics and anorexia nervosa: a review. Eur. Eat. Disord. Rev. 2010, 18(1):10-21.
54. Miller E.A., Goldman P.S., Rosvold H.E. Delayed recovery of function folowing orbital prefrontal lesions in infant monkeys. Science 1973, 182(4109):304-306.
55. Milstein J., Elnabawi A., Vinish M., Swanson T., Enos J.K., Bailey A.M., Kolb B., Frost D.O. Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS ONE 2013, 8(2):e57308.
56. Missale C., Fiorentini C., Busi C., Collo G., Spano P.F. The NMDA/D1 receptor complex as a new target in drug development. Curr. Top. Med. Chem. 2006, 6(8):801-808.
57. Missale C., Fiorentini C., Collo G., Spano P. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J. Recept. Signal Transduct. Res. 2010, 30(5):347-354.
58. Moreau A.W., Kullmann D.M. NMDA receptor-dependent function and plasticity in inhibitory circuits. Neuropharmacology 2013, 74:23-31.
59. Oberlander T.F., Gingrich J.A., Ansorge M.S. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin. Pharmacol. Ther. 2009, 86(6):672-677.
60. O'Donnell P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur. J. Neurosci. 2012, 35(12):1866-1870.
61. Pappadopulos E., Macintyre Ii J.C., Crismon M.L., Findling R.L., Malone R.P., Derivan A., Schooler N., Sikich L., Greenhill L., Schur S.B., Felton C.J., Kranzler H., Rube D.M., Sverd J., Finnerty M., Ketner S., Siennick S.E., Jensen P.S. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY) Part II. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42(2):145-161.
62. Pappadopulos E., Rosato N.S., Correll C.U., Findling R.L., Lucas J., Crystal S., Jensen P.S. Experts' recommendations for treating maladaptive aggression in youth. J. Child Adolesc. Psychopharmacol. 2011, 21(6):505-515.
63. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic press, San Diego. 4th ed.
64. Petanjek Z., Judas M., Simic G., Rasin M.R., Uylings H.B., Rakic P., Kostovic I. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(32):13281-13286.
65. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30(6):672-679.
66. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001, 14(4):260-264.
67. Robbins T.W., Arnsten A.F. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu. Rev. Neurosci. 2009, 32:267-287.
68. Scheltema Beduin A., de Haan L. Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol. Bull. 2010, 43(3):45-81.
69. Sedvall G. PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness. Trends Neurosci. 1990, 13(7):302-308.
70. Shekelle P., Maglione M., Bagley S., Suttorp M., Mojica W.A., Carter J., Rolon C., Hilton L., Zhou A., Chen S., Glassman P., Newberry S. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, 2010/08/13 ed. Report No.: 07-EHC003-EF 2007, Agency for Healthcare Research and Quality (US), Rockville, MD.
71. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J. Clin. Psychiatry 2008, 69(Suppl. 4):21-25.
72. Simpson K.L., Weaver K.J., de Villers-Sidani E., Lu J.Y., Cai Z., Pang Y., Rodriguez-Porcel F., Paul I.A., Merzenich M., Lin R.C. Perinatal antidepressant exposure alters cortical network function in rodents. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(45):18465-18470.
73. Stoneham E.T., Sanders E.M., Sanyal M., Dumas T.C. Rules of engagement: factors that regulate activity-dependent synaptic plasticity during neural network development. Biol. Bull. 2010, 219(2):81-99.
74. Strawn J.R., Delbello M.P. Olanzapine for the treatment of bipolar disorder in children and adolescents. Expert. Opin. Pharmacother. 2008, 9(3):467-474.
75. Sun X., Wolf M.E. Nucleus accumbens neurons exhibit synaptic scaling that is occluded by repeated dopamine pre-exposure. Eur. J. Neurosci. 2009, 30(4):539-550.
76. Suzuki M., Hatano K., Sakiyama Y., Kawasumi Y., Kato T., Ito K. Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography. Synapse 2001, 41(4):285-293.
77. Szulc A., Galinska-Skok B., Waszkiewicz N., Bibulowicz D., Konarzewska B., Tarasow E. Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr. Med. Chem. 2013, 20(3):414-427.
78. Thomas T., Stansifer L., Findling R.L. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr. Clin. North Am. 2011, 58(1):173-187. (xii).
79. Vinish M., Elnabawi A., Milstein J.A., Burke J.S., Kallevang J.K., Turek K.C., Lansink C.S., Merchenthaler I., Bailey A.M., Kolb B., Cheer J.F., Frost D.O. Olanzapine treatment of adolescent rats alters adult reward behavior and nucleus accumbens function. Int. J. Neuropsychopharmacol. 2013, 1-11.
80. Wahlstrom D., White T., Luciana M. Neurobehavioral evidence for changes in dopamine system activity during adolescence. Neurosci. Biobehav. Rev. 2010, 34(5):631-648.
81. Wang X., Zhong P., Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J. Neurosci. 2002, 22(21):9185-9193.
82. Weller E.B., Weller R.A. Olanzapine as treatment for children and adolescents with Tourette's syndrome. Curr. Psychiatry Rep. 2009, 11(2):95-96.
83. West A.R., Floresco S.B., Charara A., Rosenkranz J.A., Grace A.A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann. N. Y. Acad. Sci. 2003, 1003:53-74.
84. Xu S., Ji Y., Chen X., Yang Y., Gullapalli R.P., Masri R. In vivo high-resolution localized (1) H MR spectroscopy in the awake rat brain at 7T. Magn. Reson. Med. 2013, 69(4):937-943.
85. Yadav P.N., Abbas A.I., Farrell M.S., Setola V., Sciaky N., Huang X.P., Kroeze W.K., Crawford L.K., Piel D.A., Keiser M.J., Irwin J.J., Shoichet B.K., Deneris E.S., Gingrich J., Beck S.G., Roth B.L. The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 2011, 36(3):638-651.
86. Zuddas A., Zanni R., Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur. Neuropsychopharmacol. 2011, 21(8):600-620.